— Research note —
Pentadeca Arginate (PDA)
Arginate salt form of a BPC-related pentadecapeptide investigated in early research contexts for tissue repair and stability characteristics.
Pentadeca Arginate (PDA) is a 15-amino-acid peptide presented in research catalogs as an arginate salt formulation of a sequence closely related to the well-characterized body protection compound BPC-157. The arginate counterion is reported to confer improved aqueous solubility and stability characteristics relative to the acetate salt form of the parent peptide, although peer-reviewed characterization data specifically comparing the salt forms remains limited.
The peptide backbone reflects the same 15-residue pentadecapeptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) that was identified by the Sikiric group at the University of Zagreb School of Medicine in the early 1990s from a partial sequence of body protection compound isolated from human gastric juice. The extensive preclinical literature on the parent BPC-157 molecule informs the scientific framework around PDA, although specific published research on the arginate salt formulation is comparatively sparse.
Researchers have used pentadecapeptides of this sequence as tool molecules for studies of angiogenesis, gastrointestinal mucosal integrity, tendon and ligament healing models, and the nitric oxide system. Reported observations in rodent preclinical models include accelerated capillary network formation in injury settings, upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), modulation of dopaminergic and serotonergic systems in brain-gut axis studies, and effects on collagen deposition in tendon-injury models.
The arginate formulation is supplied here for laboratory research use only and is not intended for human consumption. Researchers should note that head-to-head comparisons of the arginate and acetate salt forms in standardized preclinical assays would strengthen the empirical basis for any pharmacological distinction between the two formulations.
Mechanism
The pentadecapeptide sequence shared between PDA and BPC-157 has been reported in preclinical literature to engage multiple molecular pathways relevant to tissue repair. Upregulation of VEGFR2 expression and signaling has been observed in endothelial preparations, with corresponding increases in capillary tube formation in Matrigel assays and accelerated revascularization in rodent injury models.
Activation of the nitric oxide system, including modulation of endothelial nitric oxide synthase activity, has been documented in cardiovascular and gastrointestinal models. The peptide has been reported to engage the brain-gut axis through effects on dopaminergic, serotonergic, and GABAergic neurotransmission, observations that derive from rodent behavioral and neurochemical studies. Additional reports describe effects on growth hormone receptor expression in tendon fibroblasts and on transcription factor early growth response 1 (EGR-1) in tendon healing preparations. The arginate counterion is proposed to affect dissolution and stability rather than receptor-level pharmacology.
Research history
The parent pentadecapeptide sequence underlying PDA was identified by Sikiric and colleagues at the University of Zagreb in the early 1990s through fractionation of body protection compound from human gastric juice. The Zagreb group's foundational publications from 1991 through 1999 established the gastric cytoprotection profile in rodent ulcer models, followed by characterization of effects on tendon healing, fistula closure, and central nervous system models.
The arginate salt formulation entered the research-chemical market in the early 2020s as suppliers responded to interest in alternative counterion presentations of the parent peptide. The arginate counterion is reported to confer improved solubility relative to the acetate form, though comprehensive comparative characterization in peer-reviewed literature remains an area for continued research.
Independent research groups in Croatia, Korea, Japan, and the United States have continued to publish on the parent pentadecapeptide sequence through 2025, with studies spanning gastrointestinal protection, tendon and ligament repair, cardiovascular models, and brain-gut axis investigations. The arginate formulation specifically appears in research-chemical catalogs but has not been the subject of extensive independent peer-reviewed pharmacological characterization, an area researchers have flagged as warranting further study.
References
- Sikiric P, et al. 2010. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. PMID: 20388092
- Sikiric P, et al. 2018. Brain-gut Axis and Pentadecapeptide BPC 157. Curr Neuropharmacol. PMID: 29976912
- Chang CH, et al. 2011. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. PMID: 21358592
- Seiwerth S, et al. 2014. BPC 157 and standard angiogenic growth factors. Curr Pharm Des. PMID: 24138729
- Tkalcevic VI, et al. 2007. Enhancement by PL 14736 of granulation and collagen organization in healing wounds. Eur J Pharmacol. PMID: 17574232
- Sikiric P, et al. 2020. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disturbances in Presentation of the Heart. Curr Pharm Des.
Do you have any questions about Pentadeca Arginate (PDA)?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.